These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 3300174)

  • 1. A controlled study of the influence of continuous subcutaneous insulin infusion treatment on diabetic retinopathy during pregnancy.
    Laatikainen L; Teramo K; Hieta-Heikurainen H; Koivisto V; Pelkonen R
    Acta Med Scand; 1987; 221(4):367-76. PubMed ID: 3300174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Continuous insulin infusion therapy and retinopathy in patients with type I diabetes.
    Helve E; Laatikainen L; Merenmies L; Koivisto VA
    Acta Endocrinol (Copenh); 1987 Jul; 115(3):313-9. PubMed ID: 3303785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diabetic retinopathy after 3 years' treatment with continuous subcutaneous insulin infusion (CSII).
    Olsen T; Richelsen B; Ehlers N; Beck-Nielsen H
    Acta Ophthalmol (Copenh); 1987 Apr; 65(2):185-9. PubMed ID: 3300140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continuous subcutaneous insulin infusion (CSII) in pregnant diabetic women.
    Mancuso S; Caruso A; Lanzone A; Bianchi V; Massidda M; Codipietro F; Fulghesu AM
    Acta Endocrinol Suppl (Copenh); 1986; 277():112-6. PubMed ID: 3532661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of 1 year of near-normal blood glucose levels on retinopathy in insulin-dependent diabetics.
    Lauritzen T; Frost-Larsen K; Larsen HW; Deckert T
    Lancet; 1983 Jan; 1(8318):200-4. PubMed ID: 6130243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Continuous subcutaneous insulin infusion vs intensive conventional insulin therapy in pregnant diabetic women: a systematic review and metaanalysis of randomized, controlled trials.
    Mukhopadhyay A; Farrell T; Fraser RB; Ola B
    Am J Obstet Gynecol; 2007 Nov; 197(5):447-56. PubMed ID: 17678864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The response of diabetic retinopathy to 41 months of multiple insulin injections, insulin pumps, and conventional insulin therapy.
    Brinchmann-Hansen O; Dahl-Jørgensen K; Hanssen KF; Sandvik L
    Arch Ophthalmol; 1988 Sep; 106(9):1242-6. PubMed ID: 3046587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of insulin infusion pump use on diabetic retinopathy.
    Kelly TM; Sanborn GE; Haug PJ; Edwards CQ
    Arch Ophthalmol; 1984 Aug; 102(8):1156-9. PubMed ID: 6466177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Continuous subcutaneous insulin infusion (CSII) in pregnant diabetic patients.
    Caruso A; Lanzone A; Bianchi V; Massidda M; Castelli MP; Fulghesu AM; Mancuso S
    Prenat Diagn; 1987; 7(1):41-50. PubMed ID: 3823006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 36 months continuous subcutaneous insulin infusion (CSII) in insulin dependent diabetes (IDDM)--influence on early stages of retinopathy, nephropathy and neuropathy--psychological analysis.
    Bibergeil H; Hüttl I; Felsing W; Felsing U; Seidlein I; Herfurth S; Dabels J; Reichel G; Lüder C; Albrecht G
    Exp Clin Endocrinol; 1987 Aug; 90(1):51-61. PubMed ID: 3666060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Continuous subcutaneous insulin infusion versus intensive conventional insulin therapy in type I and type II diabetic pregnancy.
    Carta Q; Meriggi E; Trossarelli GF; Catella G; Dal Molin V; Menato G; Gagliardi L; Massobrio M; Vitelli A
    Diabete Metab; 1986 Jun; 12(3):121-9. PubMed ID: 3525266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oscillatory potentials, macular recovery time, and diabetic retinopathy through 3 years of intensified insulin treatment.
    Brinchmann-Hansen O; Dahl-Jørgensen K; Hanssen KF; Sandvik L
    Ophthalmology; 1988 Oct; 95(10):1358-66. PubMed ID: 3067179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diabetic retinopathy after one year of improved metabolic control obtained by continuous subcutaneous insulin infusion (CSII).
    Olsen T; Ehlers N; Nielsen CB; Beck-Nielsen H
    Acta Ophthalmol (Copenh); 1985 Jun; 63(3):315-9. PubMed ID: 4036563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of near normoglycemia for 5 years on progression of early diabetic retinopathy and renal involvement.
    Beck-Nielsen H; Olesen T; Mogensen CE; Richelsen B; Olsen HW; Ehlers N; Charles P; Sørensen NS
    Diabetes Res; 1990 Dec; 15(4):185-90. PubMed ID: 2132407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complications and fetal outcome in diabetic pregnancy. Intensified conventional versus insulin pump therapy.
    Burkart W; Hanker JP; Schneider HP
    Gynecol Obstet Invest; 1988; 26(2):104-12. PubMed ID: 3065158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Normal eyes in type 1 diabetics stay normal after one year of treatment with continuous subcutaneous insulin pump.
    Agardh E; Bauer B; Tallroth G; Agardh CD
    Acta Ophthalmol (Copenh); 1986 Oct; 64(5):530-2. PubMed ID: 3544667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two-year experience with continuous subcutaneous insulin infusion in relation to retinopathy and neuropathy.
    Lauritzen T; Frost-Larsen K; Larsen HW; Deckert T
    Diabetes; 1985 Aug; 34 Suppl 3():74-9. PubMed ID: 4018423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of 6 months of strict metabolic control on eye and kidney function in insulin-dependent diabetics with background retinopathy. Steno study group.
    Lancet; 1982 Jan; 1(8264):121-4. PubMed ID: 6119509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid deterioration of diabetic retinopathy during treatment with continuous subcutaneous insulin infusion.
    van Ballegooie E; Hooymans JM; Timmerman Z; Reitsma WD; Sluiter WJ; Schweitzer NM; Doorenbos H
    Diabetes Care; 1984; 7(3):236-42. PubMed ID: 6734393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Continuous subcutaneous insulin infusion with short-acting insulin analogues or human regular insulin: efficacy, safety, quality of life, and cost-effectiveness.
    Radermecker RP; Scheen AJ
    Diabetes Metab Res Rev; 2004; 20(3):178-88. PubMed ID: 15133748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.